Literature DB >> 10672257

Neurotoxicity and oxidative damage of beta amyloid 1-42 versus beta amyloid 1-40 in the mouse cerebral cortex.

A M Klein1, N W Kowall, R J Ferrante.   

Abstract

Senile plaques (SP), a neuropathological hallmark of Alzheimer's disease (AD), are characterized by extracellular accumulations of beta amyloid (A beta). SP predominantly contain A beta 42 with a small amount of associated A beta 40. We determined the neurotoxic properties of A beta 42 as compared to A beta 40 by injections into the frontal cortex of three month old C57BL/6 mice. A beta 42 was associated with a significantly larger area of glial fibrillary acidic protein (GFAP) immunoreactivity and a greater density of reactive astrocytes than A beta 40. Immunohistochemical staining for markers of oxidative damage against 3-nitrotyrosine (3-NT) and 8-hydroxydeoxyguanosine (8-OHDG) were significantly more intense around the A beta 42 injection compared to the A beta 40 injection sites. These findings are consistent with previous in vitro studies and suggest that A beta 42 is more neurotoxic and may generate more free radical damage than A beta 40.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10672257     DOI: 10.1111/j.1749-6632.1999.tb07845.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  27 in total

1.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

2.  Interrelationship between Changes in the Amyloid β 42/40 Ratio and Presenilin 1 Conformation.

Authors:  Katarzyna Marta Zoltowska; Masato Maesako; Oksana Berezovska
Journal:  Mol Med       Date:  2016-07-05       Impact factor: 6.354

3.  Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease.

Authors:  Jennifer Horgan; Jose Javier Miguel-Hidalgo; Martha Thrasher; Garth Bissette
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

4.  p75NTR antagonistic cyclic peptide decreases the size of beta amyloid-induced brain inflammation.

Authors:  Mina Yaar; Bennet L Arble; Kenneth B Stewart; Nazer H Qureshi; Neil W Kowall; Barbara A Gilchrest
Journal:  Cell Mol Neurobiol       Date:  2008-09-19       Impact factor: 5.046

Review 5.  Effect of amyloids on the vesicular machinery: implications for somatic neurotransmission.

Authors:  Anand Kant Das; Rucha Pandit; Sudipta Maiti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

6.  How accurate are your simulations? Effects of confined aqueous volume and AMBER FF99SB and CHARMM22/CMAP force field parameters on structural ensembles of intrinsically disordered proteins: Amyloid-β42 in water.

Authors:  Orkid Coskuner Weber; Vladimir N Uversky
Journal:  Intrinsically Disord Proteins       Date:  2017-10-30

7.  Curcumin Dictates Divergent Fates for the Central Salt Bridges in Amyloid-β40 and Amyloid-β42.

Authors:  Bappaditya Chandra; Venus Singh Mithu; Debanjan Bhowmik; Anand Kant Das; Bankanidhi Sahoo; Sudipta Maiti; Perunthiruthy K Madhu
Journal:  Biophys J       Date:  2017-04-25       Impact factor: 4.033

8.  Ion Channel Formation by Amyloid-β42 Oligomers but Not Amyloid-β40 in Cellular Membranes.

Authors:  David C Bode; Mark D Baker; John H Viles
Journal:  J Biol Chem       Date:  2016-12-07       Impact factor: 5.157

9.  Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid.

Authors:  Sang-Ho Choi; Francesca Bosetti
Journal:  Aging (Albany NY)       Date:  2009-02-11       Impact factor: 5.682

10.  Monomer Dynamics of Alzheimer Peptides and Kinetic Control of Early Aggregation in Alzheimer's Disease.

Authors:  Srabasti Acharya; Kinshuk R Srivastava; Sureshbabu Nagarajan; Lisa J Lapidus
Journal:  Chemphyschem       Date:  2016-09-15       Impact factor: 3.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.